Compare Funko Inc (FNKO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Inovio Pharmaceuticals Inc — how do they compare? Funko Inc trades at $5.75 (market cap $315.21M), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Funko Inc is far larger — about 3.3× Inovio Pharmaceuticals Inc's market cap, and Funko Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FNKO | INO | |
|---|---|---|
Market Cap | $315.21M | $96.26M |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $2.87 |
52-Week Low | $2.46 | $1.05 |
Enterprise Value | $560.25M | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.55, down 2.46% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/S ratio of 0.34 and strong gross margins near 40%, but negative net income and ROE. Recent quarters have seen earnings beats against expectations, and analyst sentiment leans positive with a 42.86% buy rating and no sell recommendations. News highlights new product launches and a strong Q1 2026 report.
The outlook balances product-driven revenue potential against persistent profitability challenges. Investment opportunity lies in the low valuation multiple and recent earnings momentum, but risks include sustained negative margins, high debt levels, and volatile cash flows from operations.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
